Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Total Liabilities (2016 - 2026)

Sunshine Biopharma filings provide 14 years of Total Liabilities readings, the most recent being $7.0 million for Q4 2025.

  • On a quarterly basis, Total Liabilities changed 0.27% to $7.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.0 million, a 0.27% change, with the full-year FY2025 number at $7.0 million, changed 0.27% from a year prior.
  • Total Liabilities hit $7.0 million in Q4 2025 for Sunshine Biopharma, down from $7.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $7.6 million in Q4 2022 to a low of $95234.0 in Q1 2022.
  • Median Total Liabilities over the past 5 years was $5.7 million (2023), compared with a mean of $4.8 million.
  • Biggest five-year swings in Total Liabilities: plummeted 96.76% in 2022 and later skyrocketed 7840.3% in 2023.
  • Sunshine Biopharma's Total Liabilities stood at $2.0 million in 2021, then soared by 282.49% to $7.6 million in 2022, then dropped by 19.39% to $6.1 million in 2023, then rose by 14.99% to $7.1 million in 2024, then fell by 0.27% to $7.0 million in 2025.
  • The last three reported values for Total Liabilities were $7.0 million (Q4 2025), $7.3 million (Q3 2025), and $6.3 million (Q2 2025) per Business Quant data.